Cypress Bioscience Overview
- Year Founded
-
1981
- Status
-
Out of Business
- Employees
-
150
- Latest Deal Type
-
Out of Business
Cypress Bioscience General Information
Description
Developer of medical devices and therapeutics intended for the treatment of immune disorders. The company's devices provide therapeutics and personalized medicine services, enabling patients with an immune disorder to get individualized patient care.
Contact Information
Website
www.cypressbio.comCorporate Office
- 4350 Executive Drive
- Suite 325
- San Diego, CA 92121
- United States
Corporate Office
- 4350 Executive Drive
- Suite 325
- San Diego, CA 92121
- United States
Cypress Bioscience Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Out of Business | 01-Aug-2011 | Completed | Out of Business | |||
| 9. Buyout/LBO | 15-Dec-2010 | Completed | Generating Revenue | |||
| 8. PIPE | 30-May-2008 | Completed | Generating Revenue | |||
| 7. PIPE | 14-Jun-2004 | Completed | Generating Revenue | |||
| 6. PIPE | 11-Apr-2003 | Completed | Generating Revenue | |||
| 5. PIPE | 02-Apr-2002 | Completed | Generating Revenue | |||
| 4. IPO | 01-Jan-1998 | Completed | Generating Revenue | |||
| 3. Later Stage VC | 01-Oct-1997 | Completed | Generating Revenue | |||
| 2. Later Stage VC | 01-Oct-1996 | $6.93M | $19.7M | Completed | Generating Revenue | |
| 1. Later Stage VC | 01-Jan-1996 | $12.8M | $12.8M | Completed | Generating Revenue |
Cypress Bioscience Patents
Cypress Bioscience Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20100286260-A1 | Milnacipran formulations | Inactive | 05-May-2009 | ||
| CA-2738952-A1 | Method for diagnosis and monitoring of disease activity and response to treatment in systemic lupus erythematosus (sle) and other autoimmune diseases | Inactive | 16-Oct-2008 | ||
| AU-2009305575-A1 | Method for diagnosis and monitoring of disease activity and response to treatment in systemic lupus erythematosus (sle) and other autoimmune diseases | Inactive | 16-Oct-2008 | ||
| EP-2347259-A2 | Method for diagnosis and monitoring of disease activity and response to treatment in systemic lupus erythematosus (sle) and other autoimmune diseases | Inactive | 16-Oct-2008 | ||
| EP-2347259-A4 | Method for diagnosis and monitoring of disease activity and response to treatment in systemic lupus erythematosus (sle) and other autoimmune diseases | Inactive | 16-Oct-2008 | G01N33/564 |
Cypress Bioscience Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Cypress Bioscience Acquisitions (2)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Cellatope | 01-Feb-2009 | Diagnostic Equipment | |||
| Proprius Pharmaceuticals | 25-Feb-2008 | Merger/Acquisition | Pharmaceuticals |
Cypress Bioscience FAQs
-
When was Cypress Bioscience founded?
Cypress Bioscience was founded in 1981.
-
Who is the founder of Cypress Bioscience?
R. Gendreau MD is the founder of Cypress Bioscience.
-
Where is Cypress Bioscience headquartered?
Cypress Bioscience is headquartered in San Diego, CA.
-
What is the size of Cypress Bioscience?
Cypress Bioscience has 150 total employees.
-
What industry is Cypress Bioscience in?
Cypress Bioscience’s primary industry is Therapeutic Devices.
-
Is Cypress Bioscience a private or public company?
Cypress Bioscience is a Private company.
-
What is Cypress Bioscience’s current revenue?
The current revenue for Cypress Bioscience is .
-
How much funding has Cypress Bioscience raised over time?
Cypress Bioscience has raised $77.2M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
